ABUS compared with OMEX: revenue, margins and what each company keeps, and the suppliers and customers both name

ABUSArbutus Biopharma Corp

Mkt capRevenueRevenue

OMEXOdyssey Marine Exploration Inc

Mkt capRevenueRevenue

Compare

ABUSArbutus Biopharma Corp

OMEXOdyssey Marine Exploration Inc

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Supply-chain overlap

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Supply-chain overlap

direct ties · both sidesSources ›

direct ties · both sides

Only ABUS 9

MRNAModernacustomer

ALNYAlnylam Pharmaceuticalscustomer

ASMBAssembly Biosciencessupplier

—Qilu Pharmaceuticalunlistedcustomer

5 more · ABUS chain ›

Shared 0

No shared counterparties.

Only OMEX 4

—Poplar Fallsunlistedsupplier

—United States Small Business Administration ("SBA")unlistedsupplier

—CIC Limited ("CIC")unlistedcustomer

Role chip = supplier or customer—= no ticker (unlisted)Source: SEC EDGAR

—Ocean Minerals, LLC ("OML")unlistedcustomer

ABUSArbutus Biopharma Corp

3.66▼−0.41%· post 3.66

Mkt cap$723.1MRevenue$1MQ2 FY26Revenue$14MFY25

OMEXOdyssey Marine Exploration Inc

11.04▼−0.28%· post 10.90

ClosedNov 6 '26

Mkt cap$26.0MRevenue$108,913Q3 FY26Revenue$353,719FY25

Compare

ClosedNov 6 '26

ABUSArbutus Biopharma Corp

OMEXOdyssey Marine Exploration Inc

3.66▼−0.41%post 3.66

Price

11.04▼−0.28%post 10.90

$723.1M

Mkt cap

$26.0M

Q2 FY26$1M

Revenue

$108,913Q3 FY26

FY25$14M

Revenue

$353,719FY25

ABUS3.66▼−0.41%vsOMEX11.04▼−0.28%ClosedNov 6 '26